Healthcare providers taking on two-sided total cost-of-care risk in Medicare Advantage (MA) are approaching an inflection point in 2027. The current challenge is not one single rule change — it’s the collision of two forces moving in opposite directions. MA plan revenue growth is tightening under the proposed Centers for Medicare and Medicaid Services (CMS) 2027 payment policies, while utilization and medical cost trends remain elevated across the industry.
Although value-based care offers meaningful upside, providers must effectively manage the evolving pressure in MA to succeed. As of April 2026, CMS projects a net average payment increase of 2.48% for calendar year (CY) 2027 (before underlying MA coding trend), with an effective growth rate of 5.33% — largely offset by risk adjustment model updates and a tighter definition of which diagnoses “count.”
At the same time, payers continue to signal volatility in MA utilization: UnitedHealth reported MA care activity increasing at twice the rate planned in early 2025, and Humana has attributed performance pressure to rising medical costs tied to increased utilization.
For provider organizations in percentage-of-premium, capitation, shared savings, or other risk arrangements linked to MA plan economics, this creates a familiar problem: If revenue growth does not keep pace with claims growth, unit economics deteriorate rapidly.
What CMS is proposing for 2027 and why it matters
CMS’s payment update is not simply “lower rates.” It is a rebalancing of how MA payments are calculated. In the CY 2027 Rate Announcement fact sheet, CMS breaks down the year-to-year impacts, with additional detail summarized in our article “Medicare Advantage Plan Economics Reset in 2027.”
- 5.33% from the effective growth rate, a 0.36% increase over the Advance Notice
- -0.17% for county rebasing and geographic adjustment changes, a new decrease that wasn’t available in the Advance Notice
- -1.12% from Part C risk model normalization, an increase of 2.1% from the Advance Notice with the termination of the proposed 2027 MA risk adjustment model
- -1.53% from diagnosis source changes (including the exclusion of diagnoses from unlinked chart review records), no change from the Advance Notice
- -0.03% from Star Ratings changes, no change from the Advance Notice
- Result: net impact of +2.48% (excluding assumed underlying MA coding trend), a 2.39% increase over the 0.09% increase in the Advance Notice
How margin pressure will shape MA plan behavior in 2027
Plans will enter the 2027 bid season with a tighter margin equation, and we should expect a more aggressive “portfolio management” posture. Stakeholders across the spectrum are already signaling this: Payer associations warn of benefit cuts and higher member costs if flat funding persists amid high utilization, and provider organizations are warning that the low-moderate increase signals instability.
From a provider-client perspective, four plan actions are most likely to show up quickly.
1. Benefit and network optimization
Plans may adjust supplemental benefits and network strategy to fit new bid constraints. These types of changes may shift utilization patterns and patient steerage in ways providers don’t directly control.
2. Contract repricing and risk reallocation
Plans are expected to pursue renegotiations to moderate fee-for-service (FFS) rate increases. This underscores the importance of providers proactively engaging in discussions about revisiting medical loss ratio (MLR) targets to remain profitable.
3. Tighter utilization management in targeted areas
Prior authorization is already extensive in MA (around 53 million requests in 2024), and appeals frequently overturn denials (80.7% of denials overturned in 2024), suggesting ongoing friction and potential care delays. Margin pressure increases the risk that utilization management (UM) becomes more stringent or more automated in high-cost categories.
4. More demanding risk adjustment requirements under increased scrutiny
CMS is explicitly proposing that diagnoses not tied to encounters — unlinked clinical response rates — should not count for payment and has signaled larger-scale audit activity in MA. Providers should anticipate plans to push for better encounter completeness, faster submissions, and stronger clinical documentation as they adhere to the new CMS rules.
Four priorities providers must act on before bids are locked
Plans are already midway through their 2027 bid submission process — the annual process of filing pricing, benefits, and financial assumptions with CMS — which means the window for proactive moves is shorter than it looks. Bid submissions for CY 2027 are due by the first Monday in June (June 1, 2026, for Part D formulary-linked bid elements, per CMS bidding instructions).
Providers should take four immediate steps.
1. Model your risk contract under “low revenue/high trend” scenarios
Build downside cases using (a) around 0%–1% net revenue trend, (b) around 2%–3% revenue trend, and (c) a cost trend assumption that reflects your MA experience. Use these to quantify the break-even risk corridor and identify which product lines (D-SNP versus non-SNP, HMO versus PPO) are most exposed. The goal is not perfect forecasting; it is identifying unacceptable loss scenarios early enough to renegotiate.
2. Push for stronger MLR targets and deal protections before bid season closes
Providers should initiate renegotiation to raise MLR targets that lead to acceptable financial outcomes. In addition to increasing MLR targets, which lead to direct revenue increases, common deal protections that are essential in a flat funding year include: risk corridors, stop-loss/outlier carveouts, explicit treatment for mid-year benefit changes, quality incentive definitions tied to measure sets, and clarity on how risk score changes flow through (and what happens if diagnoses no longer count under CMS rules).
3. Shift risk adjustment focus from “capture” to “encounter integrity”
Invest in clinician education, documentation workflows, and timeliness of encounter submissions — while strengthening compliance guardrails amid increasing scrutiny.
4. Align with the plan on Stars-relevant clinical execution
Star program changes continue to flow through rulemaking, and Star performance remains a primary driver of plan rebates and competitive benefit design. Providers should ensure their quality roadmap maps to the plan’s Star strategy, not just internal HEDIS goals.
How acting now positions providers for 2027 MA success
The 2027 MA environment is shaping up to be a real-world stress test for provider-based risk models: lower net revenue growth, tighter risk adjustment, and persistent utilization pressure.
Providers that act now — by modeling exposure, renegotiating protections, hardening coding/encounter integrity, and aligning on Stars-linked clinical performance — will be better positioned to protect margins while continuing to deliver better outcomes for MA beneficiaries.